Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments.

Abstract: Provided is a blister pack for a dry powder inhaler configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments.

Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.

Abstract: The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I).

Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.

Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Abstract: Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments.

Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.

Abstract: The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.

Abstract: The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I).

Abstract: The present invention provides pharmaceutical compositions comprising compounds of Formula (I), and methods of treating neurological disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of Formula (I).